Fast Facts
Our clinical trials portfolio includes:
- More than 40 research studies
- More than 10 Pediatric-focused studies
- Five phase-1 Trials
- First-In-Human treatments
- Investigational New Drugs developed at UF
Featured Trial
BRAVO
Patients in this study will either receive concurrent TMZ during RT and immunotherapy during and after maintenance cycles of dose-intensive TMZ (Group A) or focal radiotherapy alone and immunotherapy without maintenance DI TMZ (Group B). Immune responses during cycles of DC vaccination with or without DI TMZ will be evaluated in both treatment groups.
Subject inclusion criteria:
- Age: 3 to 21 years old
- Radiologically confirmed DIPG and patient and/or parents/guardian willing to consent to biopsy
- performance status
- Bone Marrow, Renal and Hepatic tests
Read more about the BRAVO Clinical Trial
Contact Marcia Hodik to hear more about the BRAVO Clinical Trial.
Browse or search current neurosurgery clinical trials
ACTION
Adoptive Cellular Therapy following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas
Coordinator
BRAVO
BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated with Adoptive Cellular Therapy during Recovery from Focal Radiotherapy Alone or Radiotherapy and Dose-intensified Temozolomide
Coordinator
HeadStart 4
Newly Diagnosed Children (Less than 10 Years Old) With Medulloblastoma and Other Central Nervous System Primitive Neuro-Ectodermal Tumors: Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation with Either Single-Cycle (Low Risk Patients) or Randomization (High Risk Patients) to either Single-Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue
PNOC-005
A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
PNOC 014
A Phase I Study of TAK-580 (MLN2480) for Children with Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors
PNOC 019
A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
PNOC 016
A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
PNOC 013
A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma
PNOC 008
A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with High Grade Glioma (Excluding Diffuse Intrinsic Pontine Glioma)